首页> 美国卫生研究院文献>The Oncologist >Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801

【2h】

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801

机译：一线双周吉西他滨和卡铂的随机期II研究与双周吉西他滨和Carboplatin加上老年人未处理非小细胞肺癌患者的吉西他滨：Logik0801

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 The Oncologist
作者
Koichi Takayama; Masafumi Takeshita; Koji Inoue; Masao Ichiki; Masaki Fujita; Taishi Harada; Yoshimasa Shiraishi; Hiroshi Wataya; Shoji Tokunaga; Tadaaki Yamada; Junji Uchino; Kenji Sugio;
展开▼
作者单位

展开▼
年(卷),期 2020(25),8
年度 2020
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801 [J] . Takayama Koichi, Takeshita Masafumi, Inoue Koji, The oncologist . 2020,第8期

机译：一线双周吉西他滨和卡铂的随机期II研究与双周吉西他滨和卡铂加上老年人未经处理的非小细胞肺癌患者的吉西他滨：LOGIK0801
3. Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801 [J] . Koichi Takayama, Tadaaki Yamada, Junji Uchino, The oncologist . 2020,第8期

机译：一线双周吉西他滨和卡铂的随机期II研究与双周吉西他滨和卡铂加上老年人未经处理的非小细胞肺癌患者的吉西他滨：LOGIK0801
4. Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: A randomized, phase-II study [J] . KusagayaH., InuiN., KarayamaM., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2012,第3期

机译：与吉西他滨单药治疗相比，吉西他滨和卡铂双周联合治疗老年晚期非小细胞肺癌患者：II期随机研究
5. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer [O] . Seigo Minami, Takashi Kijima, Takayuki Shiroyama, 2013

机译：紫杉醇和卡铂联合吉西他滨开关维持治疗与吉西他滨和卡铂联合吉西他滨持续维持治疗的随机II期试验在先前未治疗的晚期非小细胞肺癌中
8. Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801 [O] . Koichi Takayama, Masafumi Takeshita, Koji Inoue, 2020

机译：一线双周吉西他滨和卡铂的随机期II研究与双周吉西他滨和Carboplatin加上老年人未处理非小细胞肺癌患者的吉西他滨：Logik0801

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801

著录项

相似文献

相关主题

期刊订阅